Loading
Life sciences · Journal article
Journal of Pediatric Hematology/oncology · September 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Ovarian dysfunction is a life-altering late effect in female childhood cancer survivors (CCS), yet early identification of ovarian injury remains challenging. This study aimed to evaluate the burden and determinants of ovarian dysfunction in CCS, with a specific focus on treatment-related amenorrhea (TRA) persisting for ≥4 months. Demographic, clinical, and treatment exposure data were obtained from the hospital medical records. Menstrual and hormonal information was collected using a structured proforma. In this single-center cross-sectional study, 186 female CCS (mean age: 21±5 y) were evaluated after a mean follow-up of 10±5.6 years. Gonadotoxic exposures included chemotherapy (100%) with a mean cumulative cyclophosphamide equivalent dose (CED) of 5.1 g/m 2, pelvic or craniospinal radiotherapy (6.45%), and hematopoietic stem cell transplantation (4.8%). Hypergonadotropic TRA was observed in 24% (45/186) of survivors, and 20% (9/45) of them progressed to acute ovarian failure (AOF). On multivariable analysis, independent predictors of TRA included postpubertal status at diagnosis (OR: 20.45; CI: 4-101.5), solid tumor diagnosis (OR: 5.98; CI: 1.7-8), and CED of ≥7.5 g/m 2 (OR: 4.56; CI: 1.4-14). Prevalence of AOF aligned with established risk categories. As an easily identifiable clinical feature, TRA may help identify survivors suitable for fertility preservation counselling and surveillance for premature ovarian failure.